ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 68 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $22,000 | -86.2% | 10,800 | -74.5% | 0.00% | – |
| Q4 2021 | $159,000 | -3.6% | 42,389 | +33.0% | 0.00% | – |
| Q3 2021 | $165,000 | +175.0% | 31,881 | +127.8% | 0.00% | – |
| Q2 2021 | $60,000 | -70.4% | 13,997 | -63.4% | 0.00% | -100.0% |
| Q1 2021 | $203,000 | -32.3% | 38,213 | -31.4% | 0.00% | -50.0% |
| Q4 2020 | $300,000 | -40.6% | 55,700 | -12.0% | 0.00% | -71.4% |
| Q3 2020 | $505,000 | +1385.3% | 63,285 | +404.2% | 0.01% | +600.0% |
| Q1 2020 | $34,000 | -94.5% | 12,552 | -88.4% | 0.00% | -85.7% |
| Q4 2018 | $622,000 | +4.4% | 108,100 | +115.3% | 0.01% | -12.5% |
| Q2 2018 | $596,000 | +27.9% | 50,200 | +21.0% | 0.01% | +14.3% |
| Q1 2018 | $466,000 | +166.3% | 41,500 | +58.4% | 0.01% | +133.3% |
| Q4 2017 | $175,000 | +21.5% | 26,200 | +49.3% | 0.00% | 0.0% |
| Q3 2017 | $144,000 | – | 17,554 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $5,165,000 | 4.93% |
| Long Focus Capital Management, LLC | 4,429,491 | $9,125,000 | 1.17% |
| Endurant Capital Management LP | 2,160,890 | $4,451,000 | 1.17% |
| NEA Management Company, LLC | 17,082,611 | $35,190,000 | 1.02% |
| Matrix Capital Management Company, LP | 38,974,185 | $80,287,000 | 0.96% |
| Key Client Fiduciary Advisors, LLC | 420,447 | $866,000 | 0.68% |
| ACT CAPITAL MANAGEMENT, LLC | 90,000 | $185,000 | 0.20% |
| DAFNA Capital Management LLC | 351,064 | $723,000 | 0.19% |
| PFM Health Sciences, LP | 2,374,674 | $4,892,000 | 0.18% |
| Rock Springs Capital Management LP | 2,297,194 | $4,732,000 | 0.12% |